Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Recurrence × fludarabine × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 64 Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Lymphoma, Mantle-Cell 1 Leukemia 1 Immunoproliferative Disorders 1 Immune System Diseases 1 Hodgkin Disease 1

Interventions

3-Iodobenzylguanidine 3 ibrutinib 2 zanubrutinib 1 vorasidenib 1 tisagenlecleucel 1 talquetamab 1 sugemalimab 1 revumenib 1 pomalidomide 1 loncastuximab tesirine 1 fludarabine phosphate 1 fludarabine 1 denileukin diftitox 1 brexucabtagene autoleucel 1 axicabtagene ciloleucel 1 Whole-Body Irradiation 1 Tacrolimus 1 Panobinostat 1 Mycophenolic Acid 1 Immunotherapy, Adoptive 1 Cytarabine 1 Cyclophosphamide 1 Cord Blood Stem Cell Transplantation 1 Busulfan 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04162756 2021-10-14

ZUMA-18

Gilead Sciences

Approved for marketing

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡